386 related articles for article (PubMed ID: 10071916)
1. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
Ravn P; Clemmesen B; Christiansen C
Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.
Ravn P; Hosking D; Thompson D; Cizza G; Wasnich RD; McClung M; Yates AJ; Bjarnason NH; Christiansen C
J Clin Endocrinol Metab; 1999 Jul; 84(7):2363-8. PubMed ID: 10404804
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis.
Ravn P; Thompson DE; Ross PD; Christiansen C
Bone; 2003 Jul; 33(1):150-8. PubMed ID: 12919710
[TBL] [Abstract][Full Text] [Related]
4. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
[TBL] [Abstract][Full Text] [Related]
6. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
7. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
8. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
9. Monitoring alendronate therapy for osteoporosis.
Braga de Castro Machado A; Hannon R; Eastell R
J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
[TBL] [Abstract][Full Text] [Related]
10. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
11. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
Greenspan SL; Resnick NM; Parker RA
J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
13. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
15. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
16. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
Ravn P; Christensen JO; Baumann M; Clemmesen B
Bone; 1998 May; 22(5):559-64. PubMed ID: 9600792
[TBL] [Abstract][Full Text] [Related]
17. Biochemical markers as predictors of rates of bone loss after menopause.
Rogers A; Hannon RA; Eastell R
J Bone Miner Res; 2000 Jul; 15(7):1398-404. PubMed ID: 10893690
[TBL] [Abstract][Full Text] [Related]
18. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
Rosen CJ; Chesnut CH; Mallinak NJ
J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
[TBL] [Abstract][Full Text] [Related]
20. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women.
Wasnich RD; Ross PD; Thompson DE; Cizza G; Yates AJ
Osteoporos Int; 1999; 9(5):455-60. PubMed ID: 10550466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
